In a recent Ethics Forum [1], Drs. John Loeser and Tim Deer opined on a case study involving the question of whether a patient should be considered for the implantation of an intrathecal opioid pump. While Dr. Loeser, who has been a critic of intrathecal opioids, recommended against implantation, Dr. Deer surprised many readers by also questioning the prudence of implantation in this particular patient. As a luminary in the field of neuromodulation, this was hardly the position expected of Dr. Deer. Shortly after the publication of the Forum, we received a letter from Dr. Michael Verdolin, who suggested a paradigmatic revision of the traditional highdosage approach to intrathecal opioid therapy. Drs. Loeser and Deer were kind enough to provide us with their responses to Dr. Verdolin's letter. Finally, we recently received a letter from Drs. Daniel Doleys and Maged Hamza, who commented on the oral/intrathecal opioid relationship, the role of extraneous variables in assessing intrathecal opioid efficacy, and intrathecal opioids as only a single element in the very complex process of managing chronic pain.
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We have chosen to publish all of these letters, as we believe that they each serve to further our understanding of intrathecal opioid therapy as well as chronic pain management more broadly considered. We are pleased to provide a forum for rich public discussion of controversial topics in the field of pain management. The purpose of the Ethics Forum is clearly not to provide the "ethical answer" to the dilemmas with which clinicians and policy-makers are faced on a daily basis. Rather, our intention is to provoke thought and consideration of alternative approaches to the practice of pain medicine. We thank Drs. Verdolin, Doleys and Hamza -and of course Drs. Loeser and Deer -for their contributions, and hope that other readers will shed their reticence and follow their examples by weighing in on future controversial topics that we address. 
